Literature DB >> 10995225

Sendai virus internal fusion peptide: structural and functional characterization and a plausible mode of viral entry inhibition.

J K Ghosh1, S G Peisajovich, Y Shai.   

Abstract

Viral glycoproteins catalyze the fusion between viral and cellular membranes. The fusion protein (F(1)) of Sendai virus has two fusion peptides. One is located at its N-terminus and the other, highly homologous to the HIV-1 and RSV fusion peptides, in the interior of the F(1) protein. A synthetic peptide corresponding to the internal fusogenic domain, namely, SV-201, was found to inhibit virus-cell fusion without interfering with the binding of the virus to the target cells, thus highlighting the importance of this region in Sendai virus-induced membrane fusion. However, its detailed mechanism of inhibition remains unknown. Here, we synthesized a shorter version of SV-201, namely, SV-208, an elongated one, SV-197, and two mutants of SV-201, and compared them functionally and structurally with SV-201. In contrast to SV-201, SV-208 and the two mutants do not inhibit virus-cell fusion. The differences in the oligomerization state of these peptides in aqueous solution and within the membrane, and in their ability to bind to Sendai virions, enabled us to postulate a possible mechanism of viral entry inhibition: SV-201 binds to its target in Sendai virions before the F(1) internal fusion peptide binds to the membrane, therefore blocking the F(1) conformational change required for fusion. In addition, we further characterized the fusogenic activity of the internal fusion peptide, compared to the N-terminal one, and determined its structure in the membrane-bound state by means of fluorescence, CD, and ATR-FTIR spectroscopy. Remarkably, we found that SV-201 and its elongated form, SV-197, are highly potent in inducing fusion of the highly stable large unilamellar vesicles composed of egg phosphatidylcholine, a property found only in an extended version of the HIV-1 fusion peptide. The inhibitory activity of SV-201 and its fusogenic ability are discussed in terms of the "umbrella" model of Sendai virus-induced membrane fusion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10995225     DOI: 10.1021/bi0005963

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  Hydrophobic alpha-helices 1 and 2 of herpes simplex virus gH interact with lipids, and their mimetic peptides enhance virus infection and fusion.

Authors:  Tatiana Gianni; Romana Fato; Christian Bergamini; Giorgio Lenaz; Gabriella Campadelli-Fiume
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

2.  Heptad repeat 2 in herpes simplex virus 1 gH interacts with heptad repeat 1 and is critical for virus entry and fusion.

Authors:  Tatiana Gianni; Angela Piccoli; Carlo Bertucci; Gabriella Campadelli-Fiume
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

3.  Evidence for mixed membrane topology of the newcastle disease virus fusion protein.

Authors:  Lori W McGinnes; Julie N Reitter; Kathy Gravel; Trudy G Morrison
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

Review 4.  Mechanistic insights of host cell fusion of SARS-CoV-1 and SARS-CoV-2 from atomic resolution structure and membrane dynamics.

Authors:  Hirak Chakraborty; Surajit Bhattacharjya
Journal:  Biophys Chem       Date:  2020-07-22       Impact factor: 2.352

5.  NMR structures and localization of the potential fusion peptides and the pre-transmembrane region of SARS-CoV: Implications in membrane fusion.

Authors:  Mukesh Mahajan; Surajit Bhattacharjya
Journal:  Biochim Biophys Acta       Date:  2014-12-02

6.  Cancer immunotherapy using the Fusion gene of Sendai virus.

Authors:  Jiayu A Tai; Chin Yang Chang; Tomoyuki Nishikawa; Yasufumi Kaneda
Journal:  Cancer Gene Ther       Date:  2019-08-06       Impact factor: 5.987

7.  Toll-like receptor 4 is not involved in host defense against respiratory tract infection with Sendai virus.

Authors:  Koenraad F van der Sluijs; Leontine van Elden; Monique Nijhuis; Rob Schuurman; Sandrine Florquin; Henk M Jansen; René Lutter; Tom van der Poll
Journal:  Immunol Lett       Date:  2003-10-31       Impact factor: 3.685

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.